Afuco™ Anti-Human CDCP1 ADCC Therapeutic Antibody (RG7287), ADCC Enhanced
Anti-CDCP1 ADCC Enhanced Antibody (RG7287) is an ADCC enhanced antibody produced by our Afuco™ platform. This is a humanized glycoengineered therapeutic anti-CDCP1 antibody with superior preclinical in vivo efficacy in combination with Paclitaxel. Combining the cytostatic with RG7287 increases tumor growth inhibition compared to RG7287 alone in one xenograft model.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-140CL |
| Pricing | Inquiry |
| Host | Humanized |
| Target | CDCP1 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |